Reconciliation of classification systems defining molecular subtypes of colorectal cancer: Interrelationships and clinical implications

Cell Cycle

Volumn 13, Issue 3, 2014, Pages 353-357

  Sadanandam, Anguraj ^a,b,f   Wang, Xin ^c,g   De Sousa E Melo, Felipe ^d   Gray, Joe W ^e   Vermeulen, Louis ^c,d   Hanahan, Douglas ^b   Medema, Jan Paul ^d  

^a SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^b EPFL   (Switzerland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Oregon Health and Science University Department of Biomedical Engineering   (United States)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer subtypes; Cetuximab; CIMP; Colorectal cancer; Consensus clustering; MSI; Serrated pathway; Therapy resistance

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CLASSIFICATION ALGORITHM; CLASSIFIER; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GOBLET CELL; HUMAN; INTESTINE CELL; PHENOTYPE; STEM CELL; CLASSIFICATION; COLON TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; PATHOLOGY;

COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 84896856425     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27769     Document Type: Article

References (12)

1. De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-8; PMID:23584090; http://dx.doi.org/10. 1038/nm.3174
2. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-25; PMID:23584089; http://dx.doi.org/10.1038/nm.3175
3. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87, e3; PMID:20420947; http://dx.doi.org/10. 1053/j.gastro.2009.12.064
4. de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011; 9: 476-85; PMID:22056143; http://dx.doi.org/10.1016/j.stem.2011.10.008
5. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Muñoz P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8:511-24; PMID:21419747; http://dx.doi.org/10.1016/j.stem.2011.02.020
6. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7; PMID:22810696; http://dx.doi.org/10.1038/nature11252
7. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7; PMID:17664471; http://dx.doi.org/10.1200/JCO.2006.10.5437
8. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-53; PMID:17585334; http://dx.doi.org/10.1038/nrc2173
9. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-15; PMID:17998284; http://dx.doi.org/10.1093/annonc/mdm496
10. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics 2010; 11: 242-53; PMID:20097884; http://dx.doi.org/10. 1093/biostatistics/kxp059
11. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-27; PMID:16632515; http://dx.doi.org/10.1093/biostatistics/kxj037
12. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.1-16; PMID:15461798; http://dx.doi.org/10.1186/gb-2004-5-10-r80